Eli Lilly most esteemed pharma company for psychiatrists: Verispan

Share this article:

Psychiatrists cited Eli Lilly as the top pharmaceutical company in overall “esteem,” according to a new Verispan study.

Of the 422 psychiatrists surveyed in the Pharmaceutical Company Image 2008 study, 43% mentioned Eli Lilly. Pfizer, Johnson & Johnson, AstraZeneca and Forest came in second, third, fourth and fifth respectively.

Other Verispan data found that Eli Lilly called on psychiatrists more than any other company in the twelve month period beginning in March 2007. Eli Lilly's calls to psychiatrists increased by 25% from the previous 2006 twelve-month period. Reps for Lilly were most likely to discuss Cymbalta, Zyprexa or Strattera, according to the study.

Among physicians overall, Pfizer was held in highest regard, followed by Merck and GlaxoSmithKline. Rounding out the top ten – in descending order – were Eli Lilly, Novartis, Sanofi-Aventis, Abbott and Wyeth. Physicians said the top three positive attributes for a pharma company were “credibility,” “pricing concerns” and “R&D,” according to the study.

In other study findings, pharmacists use the internet at a greater frequency than physicians; 87% reported going online at least once a week for pharmaceutical promotion and medical information, compared with 78% of physicians. Forty-seven percent of the healthcare professionals surveyed said DTC advertising did not affect a pharma company's image. Twenty percent of consumers surveyed said pharma advertising was a motivating factor in discussing available treatment options with a physician.

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...